“I am pleased with our continued market penetration with our FSP(TM) technology, the increased number of instrument deployments and a substantial increase in adjusted EBITDA and positive cash flow generation in what continues to be a dynamic industry environment. Our full-year results reflect our team’s strong focus on execution of our growth strategy and the leadership, strength, and resilience of the Cytek platform,” said Wenbin Jiang, CEO of Cytek Biosciences (CTKB). “Looking ahead, as we continue our path to further advance Cytek as a market leader in cell analysis, the durable foundation we have built provides us with confidence in our expectations and our long-term objective of delivering sustainable growth and profitability.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTKB:
- Cytek Biosciences price target raised to $5.25 from $4.50 at Goldman Sachs
- Cytek Biosciences downgraded to Sell from Buy at Goldman Sachs
- Big banks report Q4 beats, QXO proposes to buy Beacon: Morning Buzz
- Morning Movers: Wells Fargo and Citi gain following Q4 earnings
- Cytek Biosciences sees Q4 revenue $57M-$58M, consensus $61.49M